Gerinnungsdiagnostik unter Behandlung mit direkten oralen Antikoagulanzien

Schlüsselwörter

direkte orale Antikoagulanzien - DOAK - Monitoring - Apixaban - Dabigatran - Rivaroxaban

Keywords

direct oral anticoagulants - DOAC - Monitoring - apixaban - dabigatran - rivaroxaban

• Literatur

• 1 Blättler W, Gerlach H, Hach-Wunderle V et al. S2-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. http://www.awmf.org/uploads/tx_szleitlinien/065-002_S2_Diagnostik_und_Therapie_der_Venenthrombose_und_der_Lungenembolie_06-2010_2_.pdf (letzter Zugriff 13.8.2013)
• 2 Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europ Heart J 2012; 33: 2719-2747
• 3 Douxfils J, Chatelain C, Dogné JM et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283-294
• 4 Douxfils J, Mullier F, Loosen C et al. Assessment of the impact of rivaroxaban on coagulation assays. Thromb Res 2012; 130: 956-966
• 5 Douxfils J, Mullier F, Robert S et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 2012; 107: 985-997
• 6 Endres M, Diener HC, Röther J et al. S3-Leitlinie Sekundärprophylaxe des ischämischen Insults. 2012. http://www.dgn.org/images/stories/dgn/leitlinien/LL_2012/pdf/ll_23_2012_ sekundrprophylaxe_des_ischmischen_insults.pdf (letzter Zugriff 13.8.2013)
• 7 European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Eliquis. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002148/WC500136575.pdf (letzter Zugriff 13.8.2013)
• 8 Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention of VTE in orthopedic surgery patients. Chest 2012; 141: e278S-e325S
• 9 Food and Drug Andministration (FDA). Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). 08.09.2011. NDA: 202439, Xarelto. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf (letzter Zugriff 13.8.2013)
• 10 Food and Drug Andministration (FDA). Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). 2010. NDA: 022-512 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf (letzter Zugriff 13.8.2013)
• 11 Furie KL, Goldstein LB, Albers GW et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation. Stroke 2012; 43: 3442-3453
• 12 Guyatt GH, Akl EA, Crowther M et al. Antithrombotic therapy and prevention of thrombosis. Chest 2012; 141 (Suppl. 02) e1S-801S
• 13 Hamm CW, Bassand JP, Agewall S et al. ESC-Guidelines fort he Management of acute coronary syndrome in patienta presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054
• 14 Harenberg J, Giese C, Marx S et al. Determination of dabigatran in human plasma amples. Semin Thromb Hemost 2012; 38: 16-22
• 15 Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-51
• 16 Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease. Chest 2012; 141: e419S-e494S
• 17 Koscielny J, Ziemer S, Radtke H et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10: 195-204
• 18 Lindahl TL, Baghaei F, Fagerberg Blixter I et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378
• 19 Mani H, Kasper A, Lindhoff-Last E. Labortests und Monitoring der neuen oralen Antikoagulanzien. Klinikarzt 2013; 42 (Suppl. 01) 12-19
• 20 Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013; 36: 187-194
• 21 Stangier J, Rathgen K, Staehle H et al. The pharmacokinetics, pharmacodynamic and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor in healthy male subjects. Brit J Pharmacol 2007; 64: 292-303
• 22 Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
• 23 You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation. Chest 2012; 141: e531S-e575S